How do you interpret the EBCTCG meta-analysis analyzing the magnitude of benefit of anthracyclines in early stage ER+ breast cancer?

The appreciation of studies testing the specific benefit of adding or substituting anthracyclines as adjuvant therapy for early stage breast cancer requires a historical overview (so my apologies for a very long response….). Several of the earlier trials comparing non-anthracycline therapies (primar...

For HR+ breast cancer, the benefit of anthracyclines in patients with less than 4 positive lymph nodes is very small and I tend to avoid it in that scenario. In triple negative breast cancer patients, there is a benefit to anthracyclines compared to TC but it remains to be seen whether that benefit ...

I agree with Dr. @Dr. First Last that the benefit of using anthracyclines in ER+ N0 or N1 disease is not making a significant difference. The EBCTCG manuscript states that the relative risk reduction of these chemotherapy treatments is roughly 30% of whatever absolute risk is left over after appropr...